Australia markets close in 3 hours 45 minutes

Paradigm Biopharmaceuticals Limited (PAR.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.2700-0.0150 (-5.26%)
As of 11:50AM AEST. Market open.
Currency in AUD

Valuation measures4

Market cap (intra-day) 99.85M
Enterprise value 66.59M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.17k
Price/book (mrq)2.95
Enterprise value/revenue 1.42k
Enterprise value/EBITDA -0.97

Trading information

Stock price history

Beta (5Y monthly) 0.96
52-week change 3-70.55%
S&P500 52-week change 323.57%
52-week high 31.0651
52-week low 30.2500
50-day moving average 30.3370
200-day moving average 30.4794

Share statistics

Avg vol (3-month) 3595.02k
Avg vol (10-day) 3525.83k
Shares outstanding 5350.36M
Implied shares outstanding 6369.42M
Float 8313.8M
% held by insiders 113.03%
% held by institutions 114.32%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 June 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-184,130.46%

Management effectiveness

Return on assets (ttm)-72.47%
Return on equity (ttm)-128.42%

Income statement

Revenue (ttm)42.05k
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -77.28M
Net income avi to common (ttm)-69M
Diluted EPS (ttm)-0.2300
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)33.55M
Total cash per share (mrq)0.09
Total debt (mrq)290.31k
Total debt/equity (mrq)0.86%
Current ratio (mrq)3.83
Book value per share (mrq)0.10

Cash flow statement

Operating cash flow (ttm)-78.45M
Levered free cash flow (ttm)-58M